Immunologicals focus on infrastructure expansion
with a range of flagship products in the animal health market has
become the largest animal health brand in India.
The National Dairy Development Board (NDDB) sets up Indian
Immunologicals Ltd (IIL) in 1982 with the objective of making foot and
mouth disease (FMD) vaccine available to farmers at an affordable
price. Subsequently, IIL has developed many biologicals through its own
R&D efforts and launched several vaccines in the Indian market
at affordable prices. IIL is today a market leader in veterinary
biologicals in India. It operates one of the largest plants in the
world for veterinary vaccines and is WHO-GMP and ISO-9001 certified.
IIL exports its products to several countries and exports contribute
substantially to the company’s turnover.
IIL is the largest player in veterinary vaccine market in India with a
depth in marketing throughout the country, reaching out to the smallest
of livestock keepers. Many of its products enjoy strong patronage from
veterinarians and as a result, occupy the top slots in market share.
IIL has a range of vaccines for cattle, sheep and canine segments,
combined with its presence in the formulations segment, IIL holds the
third position in the Indian animal health market.
IIL posted a biotech sales turnover of Rs 231.46 crore for the fiscal
year ended March 2009 as against Rs 196 crore in 2007-08. The company
expects to cross the Rs 300 crore revenue mark by 2010. IIL currently
employs 1,187 people and plans to hire another 150 in the coming year.
The company has invested more than Rs 30 lakh in 2008 and plans to
triple this amount by next year, mainly in R&D and
IIL’s flagship product in the animal health market is its
Raksha FMD vaccine, which is the largest animal health brand in India.
IIL meets more than 80 percent of the requirement of the vaccine in
India. With a large repository of various FMD virus strains maintained
in the laboratory, IIL is able to provide FMD vaccines of
customer’s choice and as per epidemiological requirement for
other countries. IIL is one of the main suppliers of FMD vaccine to FAO.
IIL is also a major player in the human vaccine market in India,
especially in the pediatric vaccine and the rabies product segments. In
the human vaccine market, IIL holds the fourth position. IIL exports
its products to several countries and exports contribute substantially
to the company’s turnover. Future Plans: The company has
acquired 50 acre of land in Biotech Park – Phase III near
Karkapatla to locate its new manufacturing facilities for animal
vaccines, health formulations and human vaccines. These facilities will
be ready for commercial production by mid 2011.